Foravirumab

Foravirumab is a monoclonal antibody for the prophylaxis of rabies.[1] It is under development by Sanofi/Crucell.[2]

Foravirumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	rabies virus glycoprotein
Clinical data
ATC code	none
Identifiers
CAS Number	944548-38-3^N
ChemSpider	none
UNII	377VY97V7S
ChEMBL	ChEMBL1743021^N
Chemical and physical data
Formula	C₆₄₀₀H₉₉₁₄N₁₇₁₈O₁₉₉₈S₄₄
Molar mass	144.3 kg/mol g·mol⁻¹
^NY (what is this?) (verify)

References

International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
Khardori, Nancy Misri (2011). Biologic Response Modifiers in Infectious Diseases, An Issue of Infectious Disease Clinics. London: Elsevier Health Sciences. p. 158. ISBN 9781455712076.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab^†

Viral ("-v(i)[r]-")

Human ("-viru-")	Diridavumab^§ Exbivirumab^§ Foravirumab^§ Libivirumab^§ Rafivirumab^§ Regavirumab^§ Sevirumab^† Suptavumab Tuvirumab^§
Chimeric ("-vixi-")	Cosfroviximab Larcaviximab Porgaviximab
Humanized ("-vizu-")	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab^§ Raxibacumab
Mouse ("-baco-")	Edobacomab^§
Chimeric ("-baxi-")	Pagibaximab^†
Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Human ("-toxu-")	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric ("-toxaxi-")	Obiltoxaximab
Humanized ("-toxazu-")	Urtoxazumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.